A View on the EU Critical Medicines Act to secure Pharma Supply Chains
Recommendation
26/27 June 2025
Barcelona, Spain
Supervision of the Pharmaceutical Supply Chain: Challenges and Opportunities
Register now for ECA's GMP Newsletter
An article from Bird & Bird, titled "Europe's medicine supply crisis: How the EU's bold new act aims to address supply chain vulnerabilities," discusses the European Union's proposed Critical Medicines Act (CMA), introduced in March 2025. This legislative initiative aims to tackle persistent medicine shortages and reduce the EU's reliance on non-EU countries for pharmaceutical production.
The EU has faced ongoing medicine shortages, exacerbated by the COVID-19 pandemic and geopolitical tensions. These issues have highlighted the risks of dependency on third-country manufacturing, particularly for critical medicines.
The article describes in a comprehensive way background, scope and key elements of the CMA and emphasizes that the CMA represents a significant shift in EU pharmaceutical policy, moving beyond regulatory measures to include industrial policy tools aimed at ensuring medicine availability and supply chain resilience.
For a more detailed analysis, you can read the full article here.
Related GMP News
20.05.2025Summary Data on Registration and Listing of Cosmetic Facilities and Products
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports